On Friday, Vale SA (ADR) (NYSE:VALE)’s shares declined -5.69% to $4.14.
VALE offered -35.10% EPS for prior five years. The company has -10.90% return on equity value while its ROI ratio was 6.90%. The company has $20.40 billion market capitalizations and the institutional ownership was 19.50%. Its price to book ratio was 0.49. Volatility of the stock was 5.98% for the week while for the month booked as 4.85%.
The mean estimate for the short term price target for Vale SA (ADR) (NYSE:VALE) stands at $6.18 according to 29 Analysts. The higher price target estimate for the stock has been calculated at $10.00 while the lower price target estimate is at $4.00.
Analysts mean recommendation for the stock is 3.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Vale S.A. (Vale) is a metals and mining company. The Company is also a producer of iron ore and iron ore pellets, and nickel. The Company also produces manganese ore, ferroalloys, metallurgical and thermal coal, copper, platinum group metals (PGMs), gold, silver, cobalt, potash, phosphates and other fertilizer nutrients.
Boston Scientific Corporation (NYSE:BSX)’s shares dropped -0.84% to $18.78.
BSX has beta value of 1.04. The company has the market capitalization of $25.26 billion. Return on assets ratio of the company was -2.30% while its return on equity ratio was -6.10%. ATR value of company was 0.47 while stock volatility for week was 2.31% while for month was 2.44%. Debt to equity ratio of the company was 0.91 and its current ratio was 1.50.
The mean estimate for the short term price target for Boston Scientific Corporation (NYSE:BSX) stands at $20.76 according to 23 Analysts. The higher price target estimate for the stock has been calculated at $23.00 while the lower price target estimate is at $19.00.
Analysts mean recommendation for the stock is 1.90. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which comprises Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI).
At the end of Friday’s trade, Taiwan Semiconductor Mfg. Co. Ltd. (ADR) (NYSE:TSM)‘s shares dipped -0.70% to $22.82.
TSM has market value of $111.89 billion while its EPS was booked as $1.85 in the last 12 months. The stock has 25.93 Billion shares outstanding while 21.50% shares of the company were owned by institutional investors. In the profitability analysis, the company has gross profit margin of 49.50% while net profit margin was 37.00%. Beta value of the company was 1.01; beta is used to measure riskiness of the security.
The mean estimate for the short term price target for Taiwan Semiconductor Mfg. Co. Ltd. (ADR) (NYSE:TSM) stands at $23.12 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $27.20 while the lower price target estimate is at $14.00.
Analysts mean recommendation for the stock is -3.30. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Taiwan Semiconductor Manufacturing Co., Ltd. (TSMC) is a Taiwan-based company principally engaged in the manufacturing, selling, packaging, testing and computer-aided design of integrated circuits (ICs) and other semiconductor devices and the manufacturing of masks.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.